Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03433313|
Recruitment Status : Completed
First Posted : February 14, 2018
Last Update Posted : January 20, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Drug: EG12014 Drug: Herceptin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||807 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel Systemic Therapy in HER2-Positive Early Breast Cancer|
|Actual Study Start Date :||October 16, 2018|
|Actual Primary Completion Date :||January 20, 2022|
|Actual Study Completion Date :||January 20, 2022|
Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Active Comparator: Herceptin
Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
- Determination of pathologic complete response (pCR) at time of surgery [ Time Frame: At the time of surgery (3-6 weeks after completion of neoadjuvant chemotherapy) ]pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled sentinel and/or axillary lymph nodes
- pCR at the time of surgery [ Time Frame: At the time of surgery (3-6 weeks after completion of neoadjuvant chemotherapy) ]pCR is defined as the absence of residual invasive cancer and of DICS (ypT0 ypN0) from breast tissue and sentinel/axillary lymph nodes, as assessed by central laboratory
- pCR at the time of surgery [ Time Frame: At the time of surgery (3-6 weeks after completion of neoadjuvant chemotherapy) ]pCR is defined as the absence of invasive cancer in breast tissue only (ypT0/is) as assessed by central laboratory
- Event-free survival (EFS) up to end of study (EOS) [ Time Frame: Randomization to date of progression or end of study (up to approximately 24 months or death) ]EFS is defined as time from initial randomization to the date when disease recurrence or progression (local, regional, distant or contralateral) is diagnosed according to institutional standard, or date of death of any cause, whichever is earlier
- Overall response (OR) prior to surgery [ Time Frame: At screening and prior to surgery (3-6 weeks after completion of neoadjuvant chemotherapy) ]Objective response is defined as partial response (PR) or complete response (CR) according to RECIST v1.1
- Overall survival (OS) up to End of Study (EOS) [ Time Frame: Randomization to end of study (up to approximately 24 months or death) ]OS up to EOS is defined as time from the date of initial randomization to the date of death
- Incidence of AEs [ Time Frame: From time of informed consent to end of study (up to approximately 25 months or death) ]Incidence of AEs (including severity, seriousness, and relationship to study drug) and laboratory abnormalities
- Evaluation of Immunogenicity of EG12014 and Herceptin [ Time Frame: Prior to 1st infusion of study drug, during neoadjuvant treatment, after the last dose of neoadjuvant treatment, during adjuvant treatment, and End of Treatment ]Titer of anti-drug antibodies (ADA)
- Measure serum trastuzumab concentration [ Time Frame: Prior to 1st infusion of study drug, during neoadjuvant treatment after the last dose of neoadjuvant treatment, during adjuvant treatment, and End of Treatment ]Measure serum trastuzumab concentration for EG12014 and Herceptin arms
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Provide signed and dated written informed consent before entering the study. The informed consent will cover both parts of the study (neoadjuvant part and adjuvant part).
- Female, ≥18 and ≤65 years of age.
- Histologically-confirmed invasive carcinoma of the breast (American Joint Committee on Cancer [AJCC, vs. 8.0] Stage II, IIIa).
- Operable breast cancer, planned surgical resection of breast tumor (mastectomy or lumpectomy) and sentinel or axillary lymph nodes.
- Unilateral, measurable tumor of the breast >2 cm in diameter.
- HER2 positive tumor, defined as 3+ score by IHC or fluorescence positive by FISH, as confirmed by central laboratory.
- Known estrogen receptor (ER) and progesterone receptor (PrR) status at study entry.
- Adequate bone marrow function, defined as granulocyte count of ≥1.500/µL, and platelet count of ≥100.000/µL.
Adequate hepatic and renal function, defined as:
bilirubin within normal range
alanine aminotransferase (ALT) ≤2 x upper limit of normal (ULN)
aspartate aminotransferase (AST) ≤2 x ULN
gamma glutamyl transferase (GGT) ≤3 x ULN
serum creatinine <1.5 ULN
- International normalized ratio ≤1.5×ULN (2 to 3×ULN if on anticoagulants) or prothrombin time ≤1.5×ULN; activated partial thromboplastin time ≤1.5×ULN.
- Hemoglobin concentrations ≥10 g/dL.
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- LVEF ≥55%, measured by multiple-gated acquisition (MUGA) scan or echocardiography.
- Negative pregnancy test at entry, women of childbearing potential have to use contraceptives during the course of the study.
Females with childbearing potential must provide a negative serum pregnancy test at Screening and must be using adequate birth control. Adequate birth control is defined as agreement to consistently practice an effective and accepted method of contraception throughout the duration of the study and for 7 months after study drug treatment. These methods include hormonal contraceptives, intrauterine device, or double barrier contraception (i.e., condom + diaphragm) or a male partner with documented vasectomy.
Non-childbearing potential is defined as post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3 months before study start.
- Bilateral breast cancer.
- Pregnancy or lactation or considering becoming pregnant.
- Metastases, other than sentinel/axillary lymph nodes.
- Previous treatment (chemotherapy, biologic therapy, radiation, or surgery) for invasive malignant disease or other concomitant malignancy, other than basal cell carcinoma of the skin. Previous treatment for carcinoma in situ of the cervix is allowed.
- Previous treatment with Herceptin.
- Angina pectoris or arrhythmia requiring medication; poorly controlled hypertension; history of myocardial infarction or cardiac failure, New York Heart Association (NYHA) class II or higher; clinically significant cardiac valvular disease; hemodynamic effective pericardial effusion; other cardiomyopathies; LVEF of <55%.
- Any investigational treatment less than 30 days prior to study entry, or within a time interval less than at least 5 half-lives of the investigational medicinal product, whichever is longer.
- Positive diagnostic test for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).
- History of hypersensitivity to drugs with similar chemical structures to trastuzumab.
- History of, or known current problems with, drug or alcohol abuse.
- Other serious illness, medical disorder or condition that, in the opinion of the Investigator, would make the patient unsuitable for participation in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03433313
|Responsible Party:||EirGenix, Inc.|
|Other Study ID Numbers:||
2017-003973-33 ( EudraCT Number )
|First Posted:||February 14, 2018 Key Record Dates|
|Last Update Posted:||January 20, 2023|
|Last Verified:||January 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms by Site
Antineoplastic Agents, Immunological